Astrazeneca (AZN) Current Leases (2019 - 2026)

Astrazeneca has reported Current Leases for 8 years, with the latest figure at -$2.3 billion in Q2 2026.

• On a quarterly basis, Current Leases fell 82.55% year-over-year to -$2.3 billion in Q2 2026; TTM through Jun 2026 was -$2.3 billion, a 82.55% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 27.67% from the prior year.
• Current Leases was -$2.3 billion for Q2 2026 at Astrazeneca, down from -$1.5 billion in the prior quarter.
• The five-year high for Current Leases was -$668.0 million in Q3 2022, with the low at -$2.3 billion in Q2 2026.
• Average Current Leases over 5 years is -$1.1 billion, with a median of -$955.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Leases increased 8.87% in 2022, then plunged 82.55% in 2026.
• Over 5 years, Current Leases stood at -$725.0 million in 2022, then decreased by 18.21% to -$857.0 million in 2023, then dropped by 29.87% to -$1.1 billion in 2024, then declined by 27.67% to -$1.4 billion in 2025, then tumbled by 63.41% to -$2.3 billion in 2026.
• The last three Current Leases figures came in at -$2.3 billion (Q2 2026), -$1.5 billion (Q1 2026), and -$1.4 billion (Q4 2025), per Business Quant data.